Professional
Added to YB: 2024-10-09
Pitch date: 2024-10-08
VKTX [bullish]
Viking Therapeutics, Inc.
-44.79%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$67.16
Price Target
138.00 (+272%)
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Oppenheimer Bullish on Viking Therapeutics (VKTX) with $138 PT as Higher Dose Data Approaches
VKTX: Oppenheimer PT $138. Key ObesityWeek data on higher doses of oral VK2735 crucial. Ph1 40mg showed 5.3% weight loss vs 2.1% placebo in 28 days. Higher doses (60-100mg) may reach ~6% efficacy, <40% nausea. 75% success probability: +35% upside; disappointing results: -40% downside.
Read full article (1 min)